| 1 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
MYC |
| 2 |
33779481 |
10.1080/01676830.2021.1904426 |
2022 |
Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa. |
MYC |
| 3 |
34162179 |
10.3324/haematol.2021.278743 |
2022 |
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas. |
MYC |
| 4 |
34289655 |
10.3324/haematol.2021.278638 |
2022 |
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. |
MYC |
| 5 |
34304248 |
10.1038/s41375-021-01347-6 |
2022 |
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma. |
MYC |
| 6 |
34392269 |
10.1097/PAS.0000000000001750 |
2022 |
Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity. |
MYC |
| 7 |
34456240 |
10.1097/PAI.0000000000000967 |
2022 |
Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting. |
MYC |
| 8 |
34472720 |
10.1002/cnr2.1545 |
2022 |
Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. |
MYC |
| 9 |
34510996 |
10.1080/10428194.2021.1975189 |
2022 |
<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. |
MYC |
| 10 |
34519021 |
10.1111/bjh.17815 |
2022 |
Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. |
MYC |
| 11 |
34608246 |
10.1038/s41379-021-00909-4 |
2022 |
Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. |
MYC |
| 12 |
34617271 |
10.1111/bjh.17874 |
2022 |
Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features. |
MYC |
| 13 |
34632715 |
10.1002/1878-0261.13115 |
2022 |
Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. |
MYC |
| 14 |
34637146 |
10.1111/his.14585 |
2022 |
EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. |
MYC |
| 15 |
34654055 |
10.1182/bloodadvances.2021006034 |
2022 |
Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. |
MYC |
| 16 |
34714908 |
10.1182/bloodadvances.2021005486 |
2022 |
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. |
MYC |
| 17 |
34727403 |
10.1111/pin.13182 |
2022 |
AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. |
MYC |
| 18 |
34727830 |
10.1080/10428194.2021.1998480 |
2022 |
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma. |
MYC |
| 19 |
34739417 |
10.1097/PAS.0000000000001830 |
2022 |
Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma. |
MYC |
| 20 |
34764434 |
10.1038/s41379-021-00962-z |
2022 |
BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. |
MYC |
| 21 |
34788985 |
10.3324/haematol.2021.279631 |
2022 |
Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing. |
MYC |
| 22 |
34842019 |
10.1080/10428194.2021.2008383 |
2022 |
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? |
MYC |
| 23 |
34882582 |
10.1172/JCI153283 |
2022 |
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. |
MYC |
| 24 |
34910327 |
10.1111/jop.13269 |
2022 |
Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases. |
MYC |
| 25 |
34951009 |
10.1111/bjh.17971 |
2022 |
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. |
MYC |
| 26 |
34980601 |
10.1158/1078-0432.CCR-21-2949 |
2022 |
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. |
MYC |
| 27 |
35013138 |
10.1038/s41420-021-00622-w |
2022 |
Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis. |
MYC |
| 28 |
35031886 |
10.1186/s43556-021-00066-9 |
2022 |
Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. |
MYC |
| 29 |
35036912 |
10.1177/2632010X211070774 |
2022 |
Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow. |
MYC |
| 30 |
35045798 |
10.1080/10428194.2021.2024821 |
2022 |
High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. |
MYC |
| 31 |
35046056 |
10.1158/1078-0432.CCR-21-3617 |
2022 |
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. |
MYC |
| 32 |
35054466 |
10.3390/life12010073 |
2022 |
The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma. |
MYC |
| 33 |
35082399 |
10.1038/s41417-021-00415-4 |
2022 |
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma. |
MYC |
| 34 |
35091546 |
10.1038/s41420-022-00833-9 |
2022 |
Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma. |
MYC |
| 35 |
35152630 |
10.3760/cma.j.cn112151-20210826-00604 |
2022 |
[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements]. |
MYC |
| 36 |
35183824 |
10.1016/j.prp.2022.153804 |
2022 |
Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma. |
MYC |
| 37 |
35198451 |
10.3389/fonc.2022.834288 |
2022 |
Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells. |
MYC |
| 38 |
35223507 |
10.3389/fonc.2022.824632 |
2022 |
<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS. |
MYC |
| 39 |
35231992 |
10.3760/cma.j.issn.0253-2727.2022.01.009 |
2022 |
[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis]. |
MYC |
| 40 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
MYC |
| 41 |
35266562 |
10.1002/ajh.26523 |
2022 |
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. |
MYC |
| 42 |
35279534 |
10.1016/j.theriogenology.2022.02.028 |
2022 |
Ascorbic acid regulates mouse spermatogonial stem cell proliferation in a Wnt/β-catenin/ROS signaling dependent manner. |
MYC |
| 43 |
35296646 |
10.1038/s41419-022-04684-1 |
2022 |
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. |
MYC |
| 44 |
35297566 |
10.1111/pin.13223 |
2022 |
Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements. |
MYC |
| 45 |
35299080 |
10.1016/j.anndiagpath.2022.151913 |
2022 |
HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies. |
MYC |
| 46 |
35303910 |
10.1186/s13045-022-01249-9 |
2022 |
Altered pathways and targeted therapy in double hit lymphoma. |
MYC |
| 47 |
35306137 |
10.1016/j.cellsig.2022.110311 |
2022 |
B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. |
MYC |
| 48 |
35411950 |
10.1002/cbf.3702 |
2022 |
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. |
MYC |
| 49 |
35414839 |
NA |
2022 |
Primary ovarian Burkitt lymphoma: report of a case and review of literature. |
MYC |
| 50 |
35444774 |
10.4084/MJHID.2022.018 |
2022 |
TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment. |
MYC |
| 51 |
35481444 |
10.1080/10428194.2022.2064988 |
2022 |
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation. |
MYC |
| 52 |
35482553 |
10.1002/hon.3010 |
2022 |
Targeting MYC and BCL2 by a natural compound for double-hit lymphoma. |
MYC |
| 53 |
35484682 |
10.3324/haematol.2021.280557 |
2022 |
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. |
MYC |
| 54 |
35489963 |
10.1016/j.blre.2022.100967 |
2022 |
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma. |
MYC |
| 55 |
35498426 |
10.3389/fendo.2022.846357 |
2022 |
Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. |
MYC |
| 56 |
35510016 |
10.7759/cureus.23681 |
2022 |
Incidental Pathogenic Fibrin-Associated Diffuse Large B-cell Lymphoma Found During Aorto-Biiliac Bypass. |
MYC |
| 57 |
35511691 |
10.1093/ajcp/aqac047 |
2022 |
A Combined Biomarker of Bright CD38 and MYC ≥55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma. |
MYC |
| 58 |
35538643 |
10.1002/cam4.4742 |
2022 |
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study. |
MYC |
| 59 |
35539018 |
10.1016/j.lrr.2022.100318 |
2022 |
A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement. |
MYC |
| 60 |
35578798 |
10.1002/jcp.30777 |
2022 |
Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells. |
MYC |
| 61 |
35583405 |
10.1097/DAD.0000000000002053 |
2022 |
Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma. |
MYC |
| 62 |
35595618 |
10.1016/j.clml.2022.04.010 |
2022 |
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. |
MYC |
| 63 |
35652622 |
10.4149/neo_2022_220318N300 |
2022 |
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry. |
MYC |
| 64 |
35657404 |
10.1007/s00428-022-03342-3 |
2022 |
Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. |
MYC |
| 65 |
35696785 |
10.1016/j.biomaterials.2022.121607 |
2022 |
Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma. |
MYC |
| 66 |
35705274 |
10.2169/internalmedicine.9711-22 |
2022 |
Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2. |
MYC |
| 67 |
35715938 |
10.1002/cjp2.283 |
2022 |
Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma. |
MYC |
| 68 |
35726023 |
10.1038/s41684-022-00998-x |
2022 |
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. |
MYC |
| 69 |
35774514 |
10.3389/fgene.2022.827840 |
2022 |
A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma. |
MYC |
| 70 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
MYC |
| 71 |
35787399 |
10.1016/j.jid.2022.06.005 |
2022 |
The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ΔNp73 Depletion. |
MYC |
| 72 |
35815807 |
10.1158/0008-5472.CAN-21-2454 |
2022 |
The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis. |
MYC |
| 73 |
35846201 |
10.1002/jha2.310 |
2022 |
Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report. |
MYC |
| 74 |
35869021 |
10.1016/j.clml.2022.06.011 |
2022 |
Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. |
MYC |
| 75 |
35882439 |
10.1182/bloodadvances.2022007541 |
2022 |
Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association. |
MYC |
| 76 |
35884496 |
10.3390/cancers14143434 |
2022 |
Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape. |
MYC |
| 77 |
35885931 |
10.3390/genes13071144 |
2022 |
Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group. |
MYC |
| 78 |
35916333 |
10.1002/dc.25027 |
2022 |
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review. |
MYC |
| 79 |
35916644 |
10.1097/QAI.0000000000003069 |
2022 |
Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use. |
MYC |
| 80 |
35920412 |
10.1002/jbt.23185 |
2022 |
Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. |
MYC |
| 81 |
35932211 |
10.1002/hon.3061 |
2022 |
Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification. |
MYC |
| 82 |
35952327 |
10.1200/JCO.22.00597 |
2022 |
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. |
MYC |
| 83 |
35953760 |
10.1631/jzus.B2200016 |
2022 |
HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression. |
MYC |
| 84 |
35960849 |
10.1182/blood.2022016428 |
2022 |
Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma. |
MYC |
| 85 |
35968590 |
10.3760/cma.j.issn.0253-2727.2022.06.006 |
2022 |
[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review]. |
MYC |
| 86 |
36001789 |
10.46883/2022.25920970 |
2022 |
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas. |
MYC |
| 87 |
36006771 |
10.1097/PAS.0000000000001957 |
2022 |
Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study. |
MYC |
| 88 |
36040107 |
10.1002/JLB.6MA0822-720RR |
2022 |
Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study. |
MYC |
| 89 |
36051037 |
10.1002/jha2.475 |
2022 |
B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens. |
MYC |
| 90 |
36051055 |
10.1002/jha2.457 |
2022 |
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy. |
MYC |
| 91 |
36057749 |
10.1007/s00428-022-03404-6 |
2022 |
Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. |
MYC |
| 92 |
36081566 |
10.3389/fonc.2022.941347 |
2022 |
Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. |
MYC |
| 93 |
32273478 |
10.3324/haematol.2020.251579 |
2021 |
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. |
MYC |
| 94 |
33120427 |
10.1182/blood.2020007193 |
2021 |
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. |
MYC |
| 95 |
33303632 |
10.1074/jbc.RA120.015285 |
2021 |
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. |
MYC |
| 96 |
33306213 |
10.1002/ajh.26068 |
2021 |
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. |
MYC |
| 97 |
33340851 |
10.1016/j.leukres.2020.106491 |
2021 |
Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia. |
MYC |
| 98 |
33360122 |
10.1016/j.cancergen.2020.12.004 |
2021 |
RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas. |
MYC |
| 99 |
33392349 |
10.22038/AOJNMB.2020.48887.1332 |
2021 |
Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression. |
MYC |
| 100 |
33393079 |
10.1111/his.14327 |
2021 |
Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions. |
MYC |
Datasets
Models
